anonymous
Guest
anonymous
Guest
we are all busted......
While Suboxone and buprenorphine have shown benefits in some clinical trials, many of these benefits are only attributed to reduced “craving” for opiates or retention in treatment programs. However, as outlined in a study done by Fudala et al., for the most important and relevant factor, reducing illicit drug use, Suboxone does not show improvement (Fudala et al. 2003). As outlined below, many trials utilizing buprenorphine or Suboxone fail to reduce opioid use and consequently may simply prolong, complicate, or even worsen the user’s opioid addiction. As such, we believe that the labeling for Suboxone does not adequately disclose its dangers and effectiveness. Further, we believe that Suboxone’s advertising and marketing has failed to adequately train doctors as to (i) proper diagnosis methods, (ii) dosing levels, which are could often be over-prescribed to patients, and (iii) tapering and discontinuation regimen, which is arguably the most relevant result for addiction treatment.
can u say long acting......
We are toast.